News

Through the deal Eisai, known for its Alzheimer treatment drug Aricept, will acquire the exclusive global rights for Ontak, which is FDA-approved to treat persistent or recurrent cutaneous

The extension of the agreement governs the joint research efforts by US biopharmaceutical company Trimeris and Roche on next generation fusion inhibitor (NGFI) peptides, first signed by the

“After evaluating the results of our earlier phase II clinical trial in 253 patients and after conducting additional laboratory work, we concluded that a reformulation of our original

Dyax will also perform funded research on certain targets of Serono to identify therapeutic antibodies. Under the terms of the agreement, Dyax receives technology license fees and full-time

DCVax-LB is an extension of the DCVax personalized cancer vaccine that has already shown significant delay in disease progression and in extension of survival in clinical trials in

The collaboration involves four global research sites of Boehringer Ingelheim. Under the terms of the agreement, Graffinity will receive technology access fees and success payments for the generation

The PLA2 inhibitors were developed by Lilly and Shionogi as part of their collaboration and is designed to treat acute chest syndrome (ACS) in life-threatening diseases such as

The study treated women with locally advanced breast cancer. According to the company, results were better than what would be expected from chemotherapy treatment alone. Complete tumor removal

Geron acquired rights to this technology from the Roslin Institute in 1999 and subsequently initiated patent interferences with conflicting patents held by the University of Massachusetts. The US